Back

AZD0780, a novel, oral PCSK9 inhibitor with properties allowing for broad use, food-intake independency and co-administration with other lipid lowering therapies

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy to improve outcomes in coronary disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Jaya Birgitte Rosenmeier

AstraZeneca, Gothenburg (Sweden)

7 More presentations in this session

Presentation thumbnail
Predicting individualized treatment effects of prasugrel vs ticagrelor for acute coronary syndrome: a post hoc analysis of a randomized clinical trial
Doctor N. Kruger (Boston, US)
Abstract
Presentation thumbnail
Side effects of low-dose colchicine in chronic coronary syndromes, the LoDoCo2 trial
Miss J. Jannink (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Colchicine in patients with recent myocardial infarction: a systematic review and meta-analysis of randomized controlled trials
Ms A. Moiz (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
PCSK-9 inhibitors vs. ezetimibe for secondary prevention: utilization disparities and clinical outcomes
Doctor M. Sghayyer (Birmingham, US)
Abstract Slides Video
Presentation thumbnail
Choice of monotherapy following short duration of dual-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis of randomized clinical trials
Doctor T. Fretz (Indianapolis, US)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy to improve outcomes in coronary disease

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Lipoprotein (a) and lipidemic parameters in PCSK-9 inhibitor patients. Experience from a specialized centre in Greece.
thumbnail
Congress Presentation
Efficacy of combination lipid lowering therapy in achieving low density lipoprotein cholesterol targets after one month of event in patients with acute coronary syndrome
thumbnail
Congress Presentation
Oral PCSK9 inhibitors as an emerging frontier in lipid management: a meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources